TY - JOUR
T1 - Glycolysis links reciprocal activation of myeloid cells and endothelial cells in the retinal angiogenic niche
AU - Liu, Zhiping
AU - Xu, Jiean
AU - Ma, Qian
AU - Zhang, Xiaoyu
AU - Yang, Qiuhua
AU - Wang, Lina
AU - Cao, Yapeng
AU - Xu, Zhimin
AU - Tawfik, Amany
AU - Sun, Ye
AU - Weintraub, Neal L.
AU - Fulton, David J.
AU - Hong, Mei
AU - Dong, Zheng
AU - Smith, Lois E.H.
AU - Caldwell, Ruth B.
AU - Sodhi, Akrit
AU - Huo, Yuqing
N1 - Publisher Copyright:
Copyright © 2020 The Authors, some rights reserved.
PY - 2020/8/5
Y1 - 2020/8/5
N2 - The coordination of metabolic signals among different cellular components in pathological retinal angiogenesis is poorly understood. Here, we showed that in the pathological angiogenic vascular niche, retinal myeloid cells, particularly macrophages/microglia that are spatially adjacent to endothelial cells (ECs), are highly glycolytic. We refer to these macrophages/microglia that exhibit a unique angiogenic phenotype with increased expression of both M1 and M2 markers and enhanced production of both proinflammatory and proangiogenic cytokines as pathological retinal angiogenesis–associated glycolytic macrophages/microglia (PRAGMs). The phenotype of PRAGMs was recapitulated in bone marrow–derived macrophages or retinal microglia stimulated by lactate that was produced by hypoxic retinal ECs. Knockout of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFKFB3; Pfkfb3 for rodents), a glycolytic activator in myeloid cells, impaired the ability of macrophages/microglia to acquire an angiogenic phenotype, rendering them unable to promote EC proliferation and sprouting and pathological neovascularization in a mouse model of oxygen-induced proliferative retinopathy. Mechanistically, hyperglycolytic macrophages/microglia produced large amount of acetyl–coenzyme A, leading to histone acetylation and PRAGM-related gene induction, thus reprogramming macrophages/microglia into an angiogenic phenotype. These findings reveal a critical role of glycolytic metabolites as initiators of reciprocal activation of macrophages/microglia and ECs in the retinal angiogenic niche and suggest that strategies targeting the metabolic communication between these cell types may be efficacious in the treatment of pathological retinal angiogenesis.
AB - The coordination of metabolic signals among different cellular components in pathological retinal angiogenesis is poorly understood. Here, we showed that in the pathological angiogenic vascular niche, retinal myeloid cells, particularly macrophages/microglia that are spatially adjacent to endothelial cells (ECs), are highly glycolytic. We refer to these macrophages/microglia that exhibit a unique angiogenic phenotype with increased expression of both M1 and M2 markers and enhanced production of both proinflammatory and proangiogenic cytokines as pathological retinal angiogenesis–associated glycolytic macrophages/microglia (PRAGMs). The phenotype of PRAGMs was recapitulated in bone marrow–derived macrophages or retinal microglia stimulated by lactate that was produced by hypoxic retinal ECs. Knockout of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFKFB3; Pfkfb3 for rodents), a glycolytic activator in myeloid cells, impaired the ability of macrophages/microglia to acquire an angiogenic phenotype, rendering them unable to promote EC proliferation and sprouting and pathological neovascularization in a mouse model of oxygen-induced proliferative retinopathy. Mechanistically, hyperglycolytic macrophages/microglia produced large amount of acetyl–coenzyme A, leading to histone acetylation and PRAGM-related gene induction, thus reprogramming macrophages/microglia into an angiogenic phenotype. These findings reveal a critical role of glycolytic metabolites as initiators of reciprocal activation of macrophages/microglia and ECs in the retinal angiogenic niche and suggest that strategies targeting the metabolic communication between these cell types may be efficacious in the treatment of pathological retinal angiogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85089171507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089171507&partnerID=8YFLogxK
U2 - 10.1126/SCITRANSLMED.AAY1371
DO - 10.1126/SCITRANSLMED.AAY1371
M3 - Article
C2 - 32759274
AN - SCOPUS:85089171507
SN - 1946-6234
VL - 12
JO - Science translational medicine
JF - Science translational medicine
IS - 555
M1 - eAAY1371
ER -